NovaBridge Biosciences (NBP) Accumulated Depreciation & Amortization (2021 - 2023)
NovaBridge Biosciences (NBP) posted Accumulated Depreciation & Amortization of $5.1 billion for Q4 2023, down 40.72% on a QoQ basis from $8.5 billion in Q4 2022, and down 40.72% YoY from $8.5 billion in Q4 2022.
NovaBridge Biosciences (NBP) Accumulated Depreciation & Amortization (2021 - 2023) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Accumulated Depreciation & Amortization for 3 consecutive years, with $5.1 billion the latest figure, recorded in Q4 2023.
- For the quarter ending Q4 2023, Accumulated Depreciation & Amortization fell 40.72% year-over-year to $5.1 billion; the trailing twelve-month figure through Dec 2023 stood at $5.1 billion (down 40.72% YoY), and the FY2023 full-year result was $5.1 billion, down 40.72% from the prior year.
- Accumulated Depreciation & Amortization eased to $5.1 billion in Q4 2023 per NBP's latest filing, from $8.5 billion in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $8.5 billion in Q4 2022 to a low of $5.1 billion in Q4 2023.
- Median Accumulated Depreciation & Amortization over the past 3 years was $7.1 billion (2021), compared with a mean of $6.9 billion.
- Annual changes were most pronounced in 2022 — Accumulated Depreciation & Amortization rose 19.64% — and 2023, when it plunged 40.72%.
- A 3-year view of Accumulated Depreciation & Amortization shows it stood at $7.1 billion in 2021, then grew by 19.64% to $8.5 billion in 2022, then plunged by 40.72% to $5.1 billion in 2023.
- Per Business Quant, the three latest NBP Accumulated Depreciation & Amortization figures stand at $5.1 billion (Q4 2023), $8.5 billion (Q4 2022), and $7.1 billion (Q4 2021).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | NovaBridge Biosciences | 330.39 Mn | 119.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 5.07 Bn |
| Dec 31, 2023 | 5.07 Bn |
| Dec 31, 2022 | 8.55 Bn |
| Dec 31, 2022 | 8.55 Bn |
| Dec 31, 2021 | 7.14 Bn |
| Dec 31, 2021 | 7.14 Bn |